PentixaPharm

Executive Summary

PentixaPharm is a privately held radiopharmaceutical company based in Würzburg, Germany, focused on developing a novel theranostic pair targeting the CXCR4 receptor. CXCR4 is overexpressed in more than 20 cancer types, including multiple myeloma, lymphoma, and solid tumors, and is associated with poor prognosis and metastasis. The company’s lead candidates, PentixaFor (PET imaging agent) and PentixaTher (Lu-177 labeled therapeutic peptide), form a theranostic platform that enables precise patient selection, dosimetry, and targeted radiotherapy. PentixaFor is already clinically validated for imaging CXCR4 expression, while PentixaTher is in Phase 3 development for multiple myeloma and potentially other indications. This approach leverages the dual diagnostic-therapeutic capability to personalize treatment, reduce off-target toxicity, and improve outcomes, addressing a significant unmet need in oncology. PentixaPharm has advanced PentixaTher into a pivotal Phase 3 trial, positioning the company for a potential registration package within the next 12–18 months. If successful, PentixaTher could become the first approved CXCR4-targeted radiotherapeutic, offering a new option for patients with relapsed/refractory multiple myeloma. The company benefits from strong preclinical and clinical data supporting CXCR4 targeting, a validated mechanism, and growing investor interest in radiopharmaceuticals. Key near-term catalysts include Phase 3 interim or top-line results, which could de-risk the program and attract partnership or financing opportunities. Despite being private and relatively early in its commercial journey, the precision medicine angle and Phase 3 status support a favorable risk/reward profile.

Upcoming Catalysts (preview)

• H2 2026Phase 3 Top-Line Data for PentixaTher in Multiple Myeloma60% success
• 2026Partnership or Licensing Deal for PentixaTher Commercialization50% success
• 2025FDA Orphan Drug Designation or Breakthrough Therapy Designation70% success